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Background: Synbiotics, probiotics or prebiotics are being added to infant formula to promote growth and
development in infants. Previous reviews (2007 to 2011) on term infants given probiotics or prebiotics focused on
prevention of allergic disease and food hypersensitivity. This review focused on growth and clinical outcomes in
term infants fed only infant formula containing synbiotics, probiotics or prebiotics.
Methods: Cochrane methodology was followed using randomized controlled trials (RCTs) which compared term
infant formula containing probiotics, prebiotics or synbiotics to conventional infant formula with / without placebo
among healthy full term infants. The mean difference (MD) and corresponding 95% confidence intervals (CI) were
reported for continuous outcomes, risk ratio (RR) and corresponding 95% CI for dichotomous outcomes. Where
appropriate, meta-analysis was performed; heterogeneity was explored using subgroup and sensitivity analyses.
If studies were too diverse a narrative synthesis was provided.
Results: Three synbiotic studies (N = 475), 10 probiotics studies (N = 933) and 12 prebiotics studies (N = 1563)
were included. Synbiotics failed to significantly increase growth in boys and girls. Use of synbiotics increased stool
frequency, had no impact on stool consistency, colic, spitting up / regurgitation, crying, restlessness or vomiting.
Probiotics in formula also failed to have any significant effect on growth, stool frequency or consistency. Probiotics
did not lower the incidence of diarrhoea, colic, spitting up / regurgitation, crying, restlessness or vomiting.
Prebiotics in formula did increase weight gain but had no impact on length or head circumference gain.
Prebiotics increased stool frequency but had no impact on stool consistency, the incidence of colic, spitting up /
regurgitation, crying, restlessness or vomiting. There was no impact of prebiotics on the volume of formula
tolerated, infections and gastrointestinal microflora. The quality of evidence was compromised by imprecision,
inconsistency of results, use of different study preparations and publication bias.
Authors’ conclusions: There is not enough evidence to state that supplementation of term infant formula with
synbiotics, probiotics or prebiotics does result in improved growth or clinical outcomes in term infants. There is no
data available to establish if synbiotics are superior to probiotics or prebiotics.
Keywords: Synbiotic, Probiotic, Prebiotic, Full term infantBackground
The first year of life is characterized by very rapid
growth. Weight increases by 115%, body length 34% and
head circumference 22% [1,2]. Many full term infants
lose weight after birth and take 8–10 days to regain
it back. The average infant achieves a weight gain of
approximately 1.1 to 1.2 kg/month during the first
6 months, slowing down to 0.4 to 0.5 kg/month during* Correspondence: nkmugambi@hotmail.com
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reproduction in any medium, provided the orthe second 6 months. Length increases by 3.5 to 3.9 cm/
month during the first 4 months, slowing down to
1.8 cm/month at 6 month of age [1]. At birth average
head circumference is 35 cm and increases by an esti-
mated 12 cm during the first year of life to approxi-
mately 47 cm. A faltering head circumference has
serious implications for neural growth, maturation and
is diagnostic for possible problems of brain growth [2].
Monitoring growth (weight, length and head circumfer-
ence) evaluates the overall health of the infant and deter-
mines adequacy of nutritional intake [1].ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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crease infections, probiotics, prebiotics are added to
infant formula to promote an intestinal micro flora
resembling that of breastfed infants [3]. The intestinal
micro flora of breastfed infants have a greater concentra-
tion of bifidobacteria and fewer potentially pathogenic
bacteria compared to formula fed infants. Probiotics are
“live microorganisms” which when administered in
adequate amounts confer a health benefit to the host [3].
The main probiotic organisms used worldwide belong to
the genera Lactobacillus and Bifidobacteria and are
found in the gastrointestinal micro flora [3,4]. Probiotics
are consumed in the form of fermented food, dairy pro-
ducts, infant and toddler formula. Prebiotics are non-
digestible food ingredients that benefit the host by
selectively stimulating the growth and/or activity of one
or a limited number of bacteria in the colon and thereby
improving the host’s health [4,5]. The most widely stud-
ied prebiotics are inulin, fructooligosaccharide (FOS)
and galactooligosaccharide (GOS) which are plant stor-
age carbohydrates in vegetables, cereals and fruit. Fruc-
tooligosaccharide and inulin are added to different foods
as fat and sugar replacements to improve texture or for
their functional benefits [5-8].
Probiotics improve health in different ways [3,9]. The
health benefits conferred by probiotic bacteria are strain
specific [3,9]. Some strains increase phagocytic activity
of peripheral blood leukocytes, others strains promote
production of mucosal antibodies reducing the trans-
mucosal transfer of antigens. This strengthens the
mucosal barrier function [10-12]. Other probiotic strains
increase cytokine production such as interleukin 6 (IL-6)
[13]. In healthy people probiotics rarely cause disease.
The risk of developing bacteraemia from ingested lacto-
bacilli is less than 1 per 1 million users; risk of develop-
ing fungaemia (from Saccharomyces Boulardii) is less
than1 per 5.6 million users [14-16]. In many studies on
infants, C- reactive protein (CRP) and IL-6 have been
used to diagnose the early onset of infection [17,18].
CRP is an acute phase protein, blood levels begin to rise
to 10 – 1000 fold from 1 ug/ml within 4–6 hours at the
onset of an infective or inflammatory process. C- reactive
protein has a relatively short half-life making it useful
in monitoring infection, inflammation and response
to treatment [19]. IL-6 is a pro-inflammatory cytokine
which stimulates the production of acute phase pro-
teins (such as CRP) [20]. It is readily detected in serum
during inflammation and indicates the presence of
infection [18,19].
Adding prebiotics to formula stimulates the growth of
beneficial bacteria (such as bifidobacteria, lactobacilli) in
the gastrointestinal tract to levels found in breastfed
infants [9,21]. As these beneficial bacteria increase, they
occupy more of the “microbiological niches” in theintestine excluding pathogens. This improves the gut
mucosal barrier, prevents infections with enteric patho-
gens or trans-located gut bacteria [22,23]. Prebiotics
have a good safety record at levels found in existing
food components. Flatulence or abdominal bloating is
reported at doses greater than 20g / day. Abdominal
cramps or diarrhoea are reported at doses greater than
50 g / day [23].
When probiotics and prebiotics are administered sim-
ultaneously, the combination is termed Synbiotics. The
prebiotic in the synbiotic mixture improves the survival
of the probiotic bacteria and stimulates the activity
of the host’s endogenous bacteria [9,21,24,25]. The
superiority of synbiotics compared to either probiotics
or prebiotics have not been demonstrated. No review
has examined the impact of synbiotics on clinical out-
comes in formula fed term infants. Recent systematic
reviews (published from 2007 to 2011) on the use of
probiotics or prebiotics in term infants have focused on
prevention of allergic disease and food hypersensitivity
[26,27]. Reviews on children and adults focused on
upper respiratory tract infections, antibiotic associated
diarrhoea and acute infectious diarrhoea [28-30]. This
review focused on full term infants given only infant for-
mula with synbiotics, probiotics or prebiotics.
The Human Research Ethics Committee at the Univer-
sity of Stellenbosch, South Africa reviewed the protocol,
ruled that all data to be collected for this review was
from the public domain and was therefore exempt from
ethical approval.Objectives
The objectives of this systematic review were:
1) To determine the effects of infant formula
containing synbiotics, probiotics or prebiotics on
clinical outcomes in full term infants.
2) To explore if synbiotics are superior over probiotics
or prebiotics.Methods
Criteria for considering studies for this review
All randomized controlled trials (RCTs), irrespective
of language, which compared the use of term infant
formula containing synbiotics, probiotics or prebiotics
to conventional infant formula with or without placebo
amongst healthy full term infants (>37 weeks gesta-
tion or ≥ 2.5 kg birth weight, age: 0–12 months, with
no disease, congenital abnormality, allergy or eczema)
receiving formula feeds only. Studies published as
abstracts were included if sufficient information could
be obtained to assess study quality and obtain relevant
study findings.
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Primary outcomes
Growth changes (assessed for entire study duration):
weight gain (g/day), linear growth (cm/week, mm/
month), head growth (cm/week, mm/month). Secondary
outcomes: Tolerance to formula: Stool characteristics:
frequency, consistency, diarrhoea; Gastrointestinal symp-
toms (incidence of colic, spitting up/ regurgitation,
vomiting, crying), average formula intake (mls/day).
Infections: frequency and type of infections, use of medi-
cation (antibiotic intake); Hospitalization: Number of
days in hospital. Changes in GI microflora: Changes in
colony forming units (cfu/g of stool) of bifidobacteria,
lactobacillus post intervention, colony forming units
(cfu/g of stool) of pathogens post intervention. Immune
response: C- reactive protein levels (mg/dl), Interleukin
6 (IL-6) levels (mg/dl).Search methods for identification of studies
A literature search regardless of language was conducted
on electronic databases including The Cochrane CEN-
TRAL Register for Controlled Trials (2010), EMBASE
(1980+), Scopus (1990 present), EBSCO host (1960 to
2010), PUBMED / MEDLINE (1966 to 2010), OVID
(1950 to 2010), SPORTDiscus (1960 to 2010), Web of
Science (1970 to 2010), Science Direct (1950 to 2010),
CINAHL (1981 to 2010), Science citation index (1970 to
2010), Latin American Caribbean Health Sciences litera-
ture (LILACS) (1965 to 2010), NLMGateway (1950–
1966). RCTs published in non-English language journals
were translated by independent translators who were fa-
miliar with the subject matter. The search strategy used
to search PUBMED is shown below. This search strategy
was modified to search other electronic databases.
(synbiotic* and probiotic* OR prebiotic*) AND
(FOS or fructooligosaccharide or inulin or GOS or
galactooligosaccharide) AND (infant formula* OR
infant feeding OR formula OR formula milk) AND
(infant* or baby or babies) NOT (preterm or premature
or low birth weight babies or allergy or eczema) AND
(randomized controlled trial* OR controlled clinical
trial* Or random allocation*) Limits: Humans.
We also conducted a hand search on abstracts of
major conference proceedings such as the Pediatric Aca-
demic Society meetings from 1990 (www.pas-meetings.
org, www.abstracts2view.com), cross checked references
cited in RCTs and in recent reviews (published from
2005 to 2009) for additional studies not identified by
electronic searches and specialty journals which were
not included in any database such as Pediatrika and
Chinese Journal of Microecology.To identify on-going and unpublished trials, we contacted
experts in the field, manufacturers of infant formula con-
taining probiotics and prebiotics, we searched web sites of
companies that have conducted or were conducting RCTs
on probiotics and prebiotics e.g. Pfizer (www.pfizerpro.
com/clinicaltrials), Chris Hansen Laboratory (www.chr-
hansen.com/research_development/documentation.html).
We also searched prospective trial registries such as
World Health Organization (WHO) International Clin-
ical Trials Registry Platform Search Portal (www.who.int/
trialsearch), Clinical Trials.gov register (www.clinical-
trials.gov), Current Controlled Trials metaRegister of
Controlled Trials [mRCT] (www.controlled-trials.com/
mrct) and www.clinicaltrialresults.org.
Selection of studies
One reviewer (MM) independently reviewed all
abstracts, citations and identified potentially eligible
studies. The full reports of eligible studies were retrieved
by one reviewer (MM) and the pre-specified selection
criteria applied independently by two reviewers (MM,
ML) using a study eligibility form (Figure 1). If more
than one publication of a study existed, all reports of the
study were grouped together under one study name.
Any disagreements between the reviewers were resolved
through discussion. Unresolved disagreements were
resolved by a third party. Trial authors were contacted if
eligibility was unclear.
Assessment of quality of evidence
Two reviewers (MM, ML) independently assessed the
risk of bias of included studies as described in the
Cochrane Handbook for Systematic Reviews for Inter-
ventions according to the following 6 components: 1)
allocation sequence generation; 2) allocation conceal-
ment; 3) blinding; 4) incomplete outcome data; 5) select-
ive outcome reporting; and 6) other sources of bias [31].
Where necessary, trial authors were contacted for clarifi-
cation on the methodology of their studies. Any dis-
agreements regarding risk of bias were resolved through
discussion between MM, ML and RB. The quality of
evidence was assessed using guidelines from the Grading
of Recommendations Assessment, Development and Evalu-
ation Working Group (GRADE), www.gradeworkinggroup.
org (accessed 2012-06-07).
Data extraction and management
Two reviewers (MM, ML) independently extracted data
using a pretested data extraction form. The reviewers
(MM, ML) cross checked data and resolved any differ-
ences through discussion. One reviewer (MM) entered
the data in Review Manager (RevMan 5) and the other
reviewers (AM, ML) validated the data. Trial authors
were contacted for missing data or for clarification.
Review title:
Study ID (Author last name, initials)
Refworks ID number
Date of review for eligibility (DDMMYYYY):
Title of study/article
Journal title
Year/volume/issue/page
Extractor (Last name, initials)
Type of study
Is this study a Randomized controlled study? YES UNCLEAR NO
Exclude
Intervention used 
in study:
Trial intervention Circle below
Experimental group: Term infant formula containing either probiotic(s) 
or prebiotic(s) or synbiotic(s) YES UNCLEAR NO Probiotic
Control group: Conventional term formula with or without placebo YES UNCLEAR NO Prebiotic
Note: All formulas are Cow based milk formula, no soy based formula. 
Breastmilk when used as reference only YES UNCLEAR NO Synbiotic
Study Participants Exclude
Healthy Full term infants (>37 weeks gestation or > 2.5 kg birth weight), 
Age: 0-12 months. Strictly formula fed infants only. YES UNCLEAR NO
Exclude: If infants have Congenital malformations, chromosomal 
abnormalities. Breastfed infants (unless they are used as a reference 
group) NO UNCLEAR YES
Study Outcomes. Does the study have one or more of the 
following outcomes: Exclude
Growth parameters: (weight, Height/length, Head Circum) YES UNCLEAR NO
Tolerance to feed: stool pattern (frequency, consistency), vomiting, 
diarrhoea, volume of feed tolerated YES UNCLEAR NO
Infections: frequency, type, use of meds YES UNCLEAR NO
Immune respone: CRP, IL-6, other immune system parameters YES UNCLEAR NO
Stool Microbiology: levels of bifidobacteria, lactobacilli, pathogens YES UNCLEAR NO
Hospitalization: # days in hospital, ICU (if any) YES UNCLEAR NO
Other reasons for excluding study NO Yes
Final decision Include Unclear Exclude
For 
discussion
Comments
STUDY ELIGIBILITY FORM
Clarify missing 
information
Go to next question
Go to next question
Go to next question
Put a check  )( mark in 
appropriate box.
Effects of probiotic, prebiotic and, synbiotic 
containing infant formula on clinical outcomes in 
term infants
Figure 1 Study Eligibility form.
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Results for probiotic, prebiotic and synbiotics studies
were analysed separately. No imputation measures for
missing data were applied. Trial authors were contacted
if there was missing data. Available case analysis was
used where there was missing data. The potential impact
of missing data on results is addressed in the discus-
sion section.
Heterogeneity of the trials used in the review was
assessed by visually inspecting the forest plots to detect
overlapping confidence intervals and by performing
a Chi2 test (p<0.1 was considered statistically signific-
ant because of the low statistical power of this test). An
I-square test (I2) was also used to test for inconsistencies
across studies. If the I2 exceeded 50% and visual inspec-
tion of the forest plot supported these results, this
represented substantial heterogeneity. Since all of our
meta-analyses had less than ten studies, the assessment
of publication bias using funnel plots could not be done
[31]. If the included studies were not clinically diverse and
had similar outcome measures, a meta-analysis was carried
out in Review Manager (RevMan 5) by two reviewers (AM,
MM). The random effects meta-analysis model was ap-
plied to all meta-analyses since the studies were clinically
heterogeneous in terms of different settings (countries),
doses and strains of synbiotics, probiotics or type of pre-
biotics, different treatment durations, and other unfore-
seen factors. The inverse-variance method was used for
continuous data and the Mantel-Haenszel method was
used for dichotomous data. For continuous outcomes the
mean difference (MD) and corresponding 95% confidence
intervals (CI) were calculated. For dichotomous outcomes,
the risk ratio (RR) and corresponding 95% CI were calcu-
lated. The source of statistical heterogeneity was explored
using subgroup and sensitivity analyses. If studies were
too diverse, no meta-analysis was conducted and a narra-
tive synthesis was provided.
Results
Results of the search and description of studies
Electronic search of available databases yielded 142 cita-
tions. After reading titles and abstracts, duplicate reports
were removed, 118 articles were screened and 55 articles
were excluded. A hand search yielded 2 more articles.
Potentially relevant full text reports were retrieved,
reviewed for eligibility and a further 38 studies were
excluded. One study was published in two other reports
[32-34]. The three studies were considered as one study
and are referred to as Moro 2006 [32]. Another study
was also published in two reports; and is referred as
Moro 2002 [35,36]. Twenty five studies (3 synbiotic, 10
probiotic and 12 prebiotic studies) and three on-going
studies were included in this review [21,24,25,37-56].
The selection process is shown in Figure 2. Table 1 givesa list of 38 studies which were excluded for: use of
breast milk or mixed feeds (12 studies), no use of pro-
biotic or prebiotic (2 studies), being a cross over study,
not RCT (5 studies), type of feed was unspecified (3 stud-
ies), different inclusion criteria or outcomes (12 studies),
no data available for end of treatment period (1 study)
and data presentation inappropriate for meta- analysis
(3 studies) [57-94]. No eligible studies were excluded for
failure to report the review’s pre-specified outcomes.
Included studies
Summary of the included synbiotics, probiotics, pre-
biotics, and on-going studies are shown in Tables 2 3,
4, 5. All studies were conducted on healthy infants
and used standard infant formula.
Synbiotic studies: Three studies (N = 475) used various
synbiotic (probiotic and prebiotic) combinations [21,24,25].
Two studies [21,24] used a probiotic combination of
Bifidobacterium longum BL999 with Lactobacillus rham-
nosus; Bifidobacterium animalis ssp lactis with Lacto-
bacillus paracasei. One study [25] used Bifidobacterium
longum alone. Dosage varied from 1 × 107 to 2 × 107 cfu/g
powder to 1.28 × 108 to 2.5 × 108 cfu/100 ml. The prebio-
tics used were a combination of 90% GOS 10% FOS
[24,25] or GOS alone [21]. The prebiotic doses ranged
from 0.24 g to 0.4 g/100ml. Treatment duration varied
from 4 months to 6 months. The synbiotic studies were
conducted in France, Italy and Netherlands. None of the
synbiotic studies reported data on volume of feed tole-
rated, hospitalization, changes in GI microflora and im-
mune response.
Probiotic studies: Ten probiotic studies (N = 933) were
included. One study [55] used a reduced protein infant
formula and one study [50] used an acidified formula
given to healthy infants born to HIV positive mothers.
The most widely studied probiotics were Bifidobacter-
ium lactis (BB-12) which was administered alone
[40,44,46,50-52]. Other probiotic strains used were
Lactobacillus reuteri and Bifidobacterium bifidum. Doses
ranged widely. For Bifidobacteria: 1.5 x 106 to 3.85 x 108
cfu/g powder and Lactobacillus: 1 x 106 to 1 x 108 cfu/g
powder. Treatment duration varied from 14 days to
7 months. The probiotic studies were conducted in
Australia (Adelaide), Belgium, Chile (Santiago), France,
Israel (Beersheva), South Africa (Johannesburg) and
USA (Iowa). None of the probiotic studies reported data
on immune response.
Prebiotic studies: Twelve prebiotic studies (N = 1563)
were included. The studied prebiotics were FOS [37],
GOS [43,47,53,54], acidic oligosaccharide [42] or a mix-
ture of GOS and FOS [32,35,39,41,49]. Two studies used
long chain FOS [32,41]. One study used poly dextrose
with GOS [56]. The doses ranged from 0.15 g to 0.8 g/
100 ml. Treatment duration ranged from 28 days to 12
Figure 2 Process of study selection.
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(Nanjing), Greece, Germany (Griefswald), Italy (Ferrara,
Milan, Turin, Verona), Spain (Los Palmas, Seville) and
USA (Iowa). None of the prebiotic studies reported data
on hospitalisation and immune response.Risk of bias
The risk of bias of the included studies was assessed
across six domains using guidelines from the Cochrane
Handbook for Systematic Reviews of Interventions (Hig-
gins 2008). See Figure 3.
Table 1 Excluded studies, with reasons for exclusion
Reasons for exclusion of studies
Use of breast milk or mixed feeds
(breast milk, formula, other milk – cow,
buffalo, goat milk)
No use of probiotic,
prebiotic
Cross over trial /
study, Not RCT
Type of feed not
clear / specified
Different inclusion criteria or outcomes Data for end of
treatment period
not available
Data presentation
inappropriate for
Meta -analysis
Allen 201061 Magne 200879 Brunser 198967 Bongers 200766 Panigrahi 200882 Augustina 200760 Isolauri 200073 Rautava 200983 Decsi 200570
Baldeon 200865 Mah 200780 Thibault 200491 Euler 200571 Karvonen 199996 Alliet 200762 Knol 200575 Rinne 200585
Chandra 200268 Rinne 200686 Kim 200774 Karvonen 200197 Bakker-Zierikzee 200563 Nopchinda 200281 Velaphi 200894
Kuitunen 200976 Saavedra 200488 Rigo 200184 Bakker-Zierikzee 200664 Rivero 200487
Kukkonen 200777 Sepp 199390 Savino 200389 Correa 200569 Urao 199992
Kukkonen 200878 Vendt 200695 Hol 200872 Van der Aa 201093
M
ugam
biet
al.N
utrition
Journal2012,11:81
Page
7
of
32
http://w
w
w
.nutritionj.com
/content/11/1/81
Table 2 Summary of 10 included probiotic studies
Probiotic studies Location Inclusion criteria Treatment used in study
groups, n =
Treatment duration Reported outcomes
Brunser 200638 Santiago - Chile 37 – 42 weeks
gestation 3000 –
4200 g birth weight
1) Probiotic: L Johnsonii La1
108 cfu/ g powder n=25
13 weeks Average formula intake (ml/kg)
2) Prebiotic: FOS 2g n= 32/L Fecal excretion of bifidobacteria,
Lctobacillus, Enterobacteria
(Log10(CFU)/g stool)
3) Breastfeeding n= 26
4) In Placebo group: Conventional
infant formula no probiotic or
prebiotic n= 33
Chouraqui 200440 France Infants < 8 months 1) Probiotic: B. lactis Strain Bb12
1.5 × 106 cfu/g powder, n=46
148 days Diarrhea, stools/day, Spitting,
regurgitation
2) In Placebo group: Conventional
infant formula no probiotic or
prebiotic, n=44
Gibson 200944 Adelaide -Australia > 37 weeks gestation,
birth weight 2500–
4500 g,<10 days old
1) Probiotic group: Bifibacterium
lactis. 3.85 × 108 cfu/g 100kcal,
n= 72
7 months Growth: Weight, length,
head circumference
Stool characteristics
(data not shown)
2) Placebo group: Conventional
infant formula no probiotic, n=70
Stools, colic, spitting up,
vomiting and restlessness
Mean daily volume of formula
intake
GI infections, Respiratory
infections
Haschke-Becher 200845 Santiago - Chile 36 - 44 weeks
gestation, birth weight
> 2500 g at 16 weeks
of age
1) Probiotic group: Lactobacillus
Johnsonii 1 × 108 cfu/g powder
yielding 0.8 to 1.1 × 108 cfu/
200 mls formula, n= 17
4 weeks Growth: Weight, length,
Formula intake
Langhendries 199546 Belgium, St Joseph-
Montegnee-Rocourt
Healthy Full term
infants
1) Probiotic group: Bifibacterium
Bifidum 106 cfu/g powder, n= 20
2 months Bifidobacteria, Bacteriodes,
Enterobacteria Log10 (CFU) / g
of faeces2) Placebo group: conventional
infant formula no probiotic, n= 20
3) Reference group: Human milk,
n= 14
Petschow 200548 Iowa, USA Healthy full term infants,
weight >2500g,
appropriate for
gestational age
(0–3 months of age)
1) Probiotic group: Lactobacillus
GG 1 × 106 cfu/g powder yielding
108 cfu/day, n=15
7 day baseline,
14 days treatment period,
14 days follow up
Stool frequency,
stool consistency
2) Probiotic group: Lactobacillus
GG 1 × 107 cfu/g powder yielding
109 cfu/day, n= 14
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Table 2 Summary of 10 included probiotic studies (Continued)
3) Probiotic group: Lactobacillus
GG 1 × 108 cfu/g powder yielding
1010 cfu/day, n= 15
4) Placebo group: Conventional
infant formula no probiotic, n= 15
Urban 200850 Johanesburg
South Africa
37 - 42 weeks gestation,
2500–4200 g birth
weight, born to HIV+
mothers but
infants tested HIV-
1) Probiotic group Acidified formula
and Bifidobacterium lactis n= 29
(cfu/g powder is not specified)
4 months (119 days) Growth: Males: Weight gain,
length and head circumference
Females: Weight gain, length
and head circumference2) No probiotic group: Acidified
formula no probiotic, n= 28
3) Placebo group: Conventional
infant formula, (whey adapted
formula), n= 28
Weizman 200551 Beer - Sheva Israel > 38 weeks gestation,
4–10 months old
1) Probiotic group: Bifidobacterium
Lactis (BB-12) 1 × 107 cfu/g powder,
n= 73
12 weeks Episodes of diarrhea,
Volume of feed / day
2) Probiotic group: Lactobacillus
reuteri 1 × 107 cfu/g powder, n= 68
Episodes of respiratory illness,
antibiotic use, clinic visits
3) Placebo group: Conventional
infant formula no probiotic, n= 60
Weizman 200652 Beer - Sheva Israel > 38 weeks gestation,
< 4 months (3–65 days
of age)
1) Probiotic group: Bifidobacterium
Lactis (BB-12) 1 × 107 cfu/g powder
yielding 2.2 × 108 cfu/180 mls
reconstituted formula, n= 20
4 weeks Growth: Weight, length,
head circumference
(final percentiles)
Stooling effort score, stooling
consistency score
2) Probiotic group: Lactobacillus
reuteri 1 × 107 cfu/g powder
yielding 2.2 × 108 cfu/180 mls
reconstituted formula , n= 20
Daily crying score and daily
crying episodes
Formula volume (mls/kg)
3) Placebo group: Conventional
infant formula no probiotic, n=19
Ziegler 200355 Iowa USA ≥ 37 weeks gestation,
Birth weight 2500g - 4500g
(6–10 days of age)
1) No probiotic group: Reduced
Protein formula no probiotic or
prebiotic n=40
112 days Growth: Males: Weight, length,
Females, weight, length
2) Probiotic group: Reduced
protein formula, Bifidobacterium
lactis 3.6 × 107 cfu/g powder
yielding 4.8 × 109 cfu/L
reconstituted formula , n= 40
Stool consistency
Crying, colic (data not shown)
Hospitalization, diarrhea,
diarrhea (No. of episodes)
3) Placebo group: Conventional
infant formula, no probiotic, n=42
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Table 3 Summary of 12 included prebiotic studies
Prebiotic studies Location Inclusion criteria Treatment used in study
groups, n =
Treatment
duration
Reported outcomes
Bettler 200637 USA <14 days postnatal age, birth
weight and current weight
between 10–90 percentiles
for age
1) Prebiotic group: FOS 1.5 g/L n=72 12 weeks Growth: Weight, length, Head circumference
2) Prebiotic group: FOS 3.0 g/L n= 74
3) Placebo group: Conventional infant
formula no prebiotic, n=66
Bruzzese 200939 Milan, Napoli,
Verona Italy
37 to 42 weeks gestation,
> 2500g birth weight, 4 to
6 months old
1) Prebiotic group: GOS, FOS (ratio 9:1)
0.4 g/100 ml n= 96
12 months Growth, Weight, length. Stool consistency
Infections: diarrhea episodes /
child 12 months, episodes of acute diarrhea,
episodes of URTI,
antibiotic use
2) Placebo group: conventional
formula with no prebiotic, N= 105
Costalos 200841 Greece Birth weight between 10th
and 90th percentiles,
no breastfeeding
after age of 14 days
1) Prebiotic group: 90% G0S 10%
LcFOS 0.4 g/100 ml n=70
6 weeks Growth: Weight gain, length and head
circumference gain
Stool frequency, consistency.
GI Microflora: Bifidobacteria, E coli
2) Placebo group: Conventional
formula no prebiotic n=−70
Fanaro 200542 Ferrara, Italy Healthy full term infants,
without antibiotic treatment
1) Prebiotic group: Acidic
Oligosaccharides 0.2 g/dl, Maltodextrin
0.2 g/dl n= 16
6 weeks Growth: Weight and length gain.
Stool consistency
Crying, regurgitation and vomiting episodes
2) Prebiotic group: Acidic
Oligosaccharides 0.2 g/dl, Neutral GOS
FOS 0.6 g/dl n= 15
Gi Microflora
3) Placebo group: Maltodextrin
at 8g/dl n=15
Fanaro 200843 Ferrara, Turin Italy,
Las Palmas,
Seville Spain
Appropriate for gestational
age, birth weight > 1500g,
4 to 6 months old
1) Prebiotic group: GOS 5 g/L n= 56 18 weeks Growth: Weight, length
Stool frequency, consistency
GI microflora: Bifidobacteria, Lactobacilli,
Bacteriodes,
Clostridia, Enterobacteriacae
Moro 200235
(Moro 2003,
considered as
one study)
Milan Italy 39 to 40 weeks gestational age 1) Prebiotic group: GOS, FOS 0.4 g/dl
n=30
28 days Growth: Weight and length gain
2) Prebiotic group: GOS FOS 0.8 g/dl
n= 27
Stool frequency, consistency
3) Placebo group: Maltodextrin at
0.8g/dl n=33
Crying, regurgitation and vomiting
4) Reference group: Breast milk n=15 Feeding volume
GI microflora: Bifidobaceria, Lactobacilli
Moro 200547 Italy Healthy full term infants,
appropriate for gestational age
1) Prebiotic group: GOS 0.8g/dl, n= 16 28 days Growth: Weight, length gain
2) Placebo group: Maltodextrin at
0. 8g/dl n=16
Feeding volume
GI microflora
Moro 200637
(Arslanoglu 2007,
Milan Italy 37 - 42 weeks gestational age 1) Prebiotic group: ScGOS Lc FOS at
8g/L, n= 104
6 months Growth: Weight gain, length gain,
head circumference
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Table 3 Summary of 12 included prebiotic studies (Continued)
Arslanoglu 2008
considered as
one study)
2) Placebo group: Maltodextrin at
8g/L, n=102
Stool frequency, consistency
Crying, regurgitation and vomiting
GI microflora: Bifidobacteria, Lactobacilli
Infectious episodes: Overall infections,
URTI, Otis Media, GI infections,
UTI, antibiotic use
Schmelzle 200349 Griefswald
Germany
37 to 42 weeks gestational age,
birth weight between 10 to
90 percentiles, exclusive
formula feeding by age
14 days old
1) Prebiotic group: 90% GOS, 10% FOS
0.8/100ml n=76
12 weeks Growth: Males - Weight gain,
length gain, head circumference
2) Placebo group: Conventional infant
formula, no prebiotic, n=78
Females - Growth: Weight gain,
length gain, head circumference
Volume of feed (formula)
GI microflora: Bifidobacteria
Xiao-Ming 200453 Nanjing China Healthy full term infants 1) Prebiotic group: Galactooligosaccharide
0.24 g/ dl n=69
6 months GI Microflora: Bifidobacteria, Lactobacilli,
E coli
2) Prebiotic formula with Human milk
n= 124
3) Placebo group: Conventional infant
formula, no prebiotic, n=52
4) Reference group: Human milk n= 26
Xiao-Ming 200854 Nanjing China > 38 weeks gestation, Birth
weight > 3kg
1) Prebiotic group 1: Galactooligosaccharide
0.24 g/ 100 ml n=37
3 months Growth: Weight gain, length gain
Stool consistency
2) Prebiotic group 2: Prebiotic formula with
Human milk n= 58
Crying, regurgitation and vomiting scores
Volume of feed
3) Placebo group: Conventional infant
formula, no prebiotic, n=45
GI Microflora: Bifidobacteria, Lactobacilli,
E coli
4) Reference group: Human milk n= 24
Ziegler 200756 USA > 37 weeks gestation, Birth
weight 2500g, solely formula
fed
1) Prebiotic group 1: Polydextrose,
Galactooligosaccharide n=58
120 days Growth: Weight gain, length gain,
head circumference
Stool frequency, consistency
2) Prebiotic group 2: Polydextrose,
Galactooligosaccharide, Lactulose
n= 48
Intolerance to formula: Vomiting, diarrhea,
excessive spitting, colic
3) Placebo group: Conventional infant
formula, no prebiotic, n=58
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Table 4 Summary of 3 included synbiotic studies
Probiotic studies Location Inclusion criteria Treatment used in study groups, n = Treatment duration Reported Outcomes
Chouraqui 200824 France (Marseille) 37 – 42 weeks, gestation,
≤ 14 days singletons,
2500 – 4500g birth weight
1) Probiotic group: Bifibacterium Longum
BL999 1.29 × 108 cfu/100 ml formula,
L.Rhamnosus 6.45 × 108 cfu/100 ml formula,
n=60
4 months, observation:
16 – 52 weeks
Growth: Length, Head circumference
Stool frequency, consistency, Incidence
of diarrhea during treatment period
Frequency of infections
2) Synbiotic group 1: Bifibacterium.Longum
BL999 1.29 × 108 cfu/100 ml, L Rhamnosus
6.45 × 108 cfu/100 ml, 90% GOS, 10% ScFOS
0.4 g/100 ml n=54
3) Synbiotic group 2: Bifibacterium Longum
BL999 2.58 × 108 cfu/100 ml, LParacasei
2.58 × 108 cfu/100 ml, 90% GOS, 10% ScFOS
0.4 g/100 ml, n=60
4) Placebo group: Conventional infant
formula no probiotic or prebiotic, n=53
Puccio 200725 Palermo Italy Healthy Full term infants
with gestational age 39 weeks
1) Synbiotic group: Bifibacterium Longum BL
999 2 × 107 Cfu/g powder, GOS 90% FOS 10%
at 4g/L, n=42, n=67
112 days Growth: Weight, length, head
circumference
Stool frequency (evacuations/day)
2) Conventional infant formula no synbiotic,
n=55
Crying, restlessness, colic, spitting
and vomiting
Volume of feed tolerated
Frequency of respiratory tract infections
Vlieger 200921 Niewegein, Netherlands Healthy Full term infants with
gestational age > 37 weeks,
< 7 days, formula fed
1) Synbiotic group: Bifibacterium animalis ssp
Lactis 1 × 107 Cfu/g powder, Lactobacillusn
paracasei 1 × 107 Cfu/g powder, GOS 0.24 g/100 ml,
n=67
6 months Growth: Weight, length, head
circumference
2) Placebo group: Prebiotic infant formula GOS
0.24 g/100 ml, n=59
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Table 5 Summary of 3 on-going studies
On-going
studies
Location Inclusion criteria Treatment used in study
groups, n =
Outcomes, Estimated date
of completion
Cabana 201057 USA >37 weeks gestation, birth
weight >2500 g and < 4500 g,
14±3 days of age on
enrollment, singleton birth,
non- breastfed, not received
solid foods.
1) Study group 1: Test starter infant
formula
Primary: Weight gain (g/day) at 14
to 112 days of life (4 months)
2) Study group 2: Test starter infant
formula with synbiotics
3) Control /placebo group: Standard
formula
Secondary: Tolerance, morbidity,
protein status, metabolic markers
December 2011
Zegerman 200958 Israel 37th and 42 week gestation,
birth weight > 2500 g,
recruitment age: 0–28 days,
non-breastfed
1) Study group 1: Dietary Supplement:
probiotic microorganism and/
or prebiotic
Primary: weight, length, head
circumference
2) Dietary Supplement: probiotic
microorganism and/or prebiotic
Secondary: Microbiology August 2012
3) Dietary Supplement: probiotic
microorganism and /or prebiotic
Ye 201059 Singapore > 37 weeks to < 42 weeks
gestation, singleton birth. Age
at enrolment < 14 days old
1) Study group 1: Standard infant
formula with prebiotics
Primary: Mean Weight gain
2) Study group: Infant formula with
synbiotics
Secondary: Digestive tolerance
December 2011
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Fifteen trials described clearly the methods used for
random sequence generation [21,24,32,37-41,43,44,46,
49-52]. Random sequence generation was done through
computer randomization [21,37,38,43,44,50-52], random
number tables [39,46] or block randomization [32,40,41].
The method used for random sequence generation
was not clearly described in 10 studies [25,35,42,45,
47,48,53-56].
Allocation concealment
In seven trials, treatment allocation was adequately con-
cealed [32,38,42,44,46,49,50]. Allocation concealment
was adequate due to central allocation using a computer
[38], use of sealed envelopes [43,44,49], pre – coded or
colour coded containers [32,50] and use of independent
staff outside of study [46]. In the rest of the 18 studies,
allocation concealment was not clearly demonstrated or
described [21,24,25,35,37,39-42,45,47,48,51-56].
Blinding
Adequate blinding of study participants, care providers
and assessors was done in 9 trials. Blinding was ensured
by using pre-coded or colour coded formula tins
[21,24,25,32,38,43,44,46,50]. In the other 16 trials, there
was not enough information given on the blinding method
to make a judgement [35,37,39-42,45,47-49,51-56].
Incomplete outcome data
Reported outcome data was satisfactory for 19 studies.
In 3 studies, there was no missing outcome data
[38,40,54]. In 16 studies, missing outcome data was
balanced across the intervention groups with similarreasons reported [21,24,25,32,37,39,41-45,49-52,55]. In
4 studies there was insufficient information given to per-
mit a judgement [35,46,47,53]. In 2 studies there were
no reasons given for missing data [48,56].
Selective reporting
In 7 studies, the pre-specified outcomes in the meth-
ods section were reported in the results section
[21,25,32,45,49,54,56]. In 18 studies the pre-specified
outcomes were not reported [24,35-44,46,48,50-55].
Other potential sources of bias
Nineteen studies appeared to be free from other poten-
tial sources of bias [21,24,25,32,38-46,49-52,54,56].
There was insufficient information given to permit a
judgment in 6 studies [35,37,47,48,53,55].
Effects of interventions
Synbiotics versus controls
Three studies (N = 475) investigated the effect of synbio-
tic administration versus no synbiotic or placebo (con-
trol group) [21,24,25].
Primary outcomes
Growth parameters
(i) Weight gain
Only one study [24] reported weight gain in
terms of grams per day (g/day). In this study,
two types of synbiotics (Type 1 and Type 2)
were evaluated and results for boys and girls
were reported separately. The results of the
two synbiotics were combined using the
Key
Low risk of bias
Unclear risk of 
bias
High risk of bias
Figure 3 Methodological qualities of included studies.
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The calculated treatment effects showed that
synbiotics failed to significantly increase
weight gain for boys (MD 0.90, 95% CI: -1.95 to
3.75, n = 81) and girls (MD 0.90, 95% CI: -1.81
to 3.61, n = 86) compared to the controls.
One study [21] reported weight gain in terms of
some score scale. A calculated treatment effect
showed that synbiotics failed to significantly
increase weight gain compared to controls (MD
−0.07, 95% CI: -0.43 to 0.29, n = 79). Since the
score scale can take negative values, the values of
mean and standard deviation in this analysis do
not necessarily imply that the data is skewed.
One study [25] reported weight gain (g/day) in
terms of mean difference (MD) and 90% CI.
These values were used in calculating the
corresponding standard error (SE). The MD and
SE were used in calculating the treatment effect
(via the generic-inverse variance method in
RevMan). Synbiotics again failed to significantly
increase weight gain compared to controls (MD
−1.09, 95% CI: -3.54 to 1.36, n= 97).(ii) Length gain
Two studies [24,25] reported length gain in
terms of millimetres per month (mm/month)
for boys and girls separately. Results from these
two studies were pooled in a meta-analysis but
for Chouraqui 2008 [24] results for the two
types of synbiotics were combined before
meta-analysis. Results from the meta-analysis
showed that synbiotics failed to significantly
increase length gain compared to controls
for both boys (MD 0.75, 95% CI: -0.66 to 2.17,
n = 126) and girls (MD 0.75, 95% CI: -0.63
to 2.13, n = 138) [Figure 4]. There was no
significant heterogeneity detected between
the two studies for boys (Chi2=0.50, df=1,
p=0.48, I2=0%) and girls (Chi2=0.53, df=1,
p=0.47, I2=0%).
One study [21] reported length gain in terms of
some score scale. A calculated treatment effect
showed that synbiotics failed to significantly
increase length gain compared to controls
(MD 0.01, 95% CI: -0.43 to 0.45, n = 79). Since
the score scale can take negative values, the values
of mean and standard deviation in this analysis do
not necessarily imply that the data is skewed.(iii) Head circumference gain
Two studies [24,25] reported head circumference
gain in terms of mm/month for boys and girls
separately. Results from these two studies were
pooled in a meta-analysis but for Chouraqui
2008 [24] results for the two types of synbiotics
Figur
Figure 4 Synbiotics versus controls, Outcome: Length gain (mm/month) for girls.
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the meta-analysis showed that synbiotics failed
to significantly increase head circumference
gain compared to controls for both boys.
(MD −0.06, 95% CI: -0.96 to 0.85, n = 126) and
girls (MD −0.05, 95% CI: -0.94 to 0.85, n = 138).
There was no significant heterogeneity detected
between the two studies for both boys (Chi2=0.64,
df=1, p=0.43, I2=0%) and girls (Chi2=0.67, df=1,
p=0.41, I2=0%).
One study [21] reported head circumference gain
in terms of some score scale. A calculated
treatment effect showed that synbiotics failed to
significantly increase head circumference gain
compared to controls (MD 0.01, 95% CI: -0.38 to
0.36, n = 79). Since the score scale can take
negative values, the values of mean and standard
deviation in this analysis do not necessarily imply
that the data is skewed.Secondary outcomes
Tolerance to formula
(i) Stool frequency
Two studies [21,25] reported stool frequency
(evacuations per day) and their results were pooled
in a meta-analysis. Synbiotics significantly
increased stool frequency compared to the controls
(MD 0.28, 95% CI: 0.08 to 0.48, n = 176) and there
was no significant heterogeneity detected between
the two trials (Chi2=0.93, df=1, p=0.33, I2=0%)
[Figure 5].
One study [25] reported stool frequency
(evacuations per day) but values for standarde 5 Synbiotics versus controls, outcome: Stool frequency (evacuations pdeviations were not given and as a result, no
treatment effect could be calculated.(ii) Stool consistency
One study [21] evaluated stool consistency using a
consistency score (1=hard to 4=watery and loose) and
a calculated treatment effect showed no significant
difference between the synbiotic and control treated
groups (MD 0.13, 95% CI: -0.15 to 0.41, n = 79).
One study [24] study reported that liquid stools
occurred significantly more frequently in the
synbiotic group compared to the control group
(OR 3.17, 95% CI: 1.59 to 3.60, n = 66).
Puccio 2007 [25] reported that data on stool
consistency showed no statistically significant
differences between the two study groups (data not
shown in study report).(iii) Incidence of colic, spitting up / regurgitation,
vomiting, crying
Data on frequency of crying, restlessness, colic,
spitting and vomiting reported by Puccio 2007 [25]
showed no statistically significant differences
between the two study groups (data not shown in
study report).
Results from Vlieger 2009 [21] showed no significant
differences in the frequency of vomiting (RR 0.46,
95% CI: 0.12 to 1.72, n = 79) and colic (RR 2.50, 95%
CI: 0.46 to 13.73, n = 79) between the two study
groups. The same study showed no difference in
crying (hours per day) between the two study groups
(MD −0.10, 95% CI: -0.46 to 0.26, n = 79).(iv) Average formula intake
One study [25] reported the mean daily intake of
formula in a graph where no values could be
retrieved.er day).
Figur
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formula in a graph where no values could be
retrieved.Infections
(i) Infections
Puccio 2007 [25] reported data on frequency of
respiratory tract infections but there were no
significant differences between the synbiotic and
control treated groups (RR 0.71, 95% CI: 0.31 to
1.59, n = 97).
Vlieger 2009 [21] reported the mean (SD) of upper
respiratory tract infections and gastrointestinal
infections (times per month) but no treatment
effect could be calculated because the data was
skewed (mean < SD).(ii) Antibiotic intake
Vlieger 2009 [21] reported the mean (SD) of the
use of antibiotics (times per month) but no
treatment effect could be calculated because the
data was skewed (mean < SD).Probiotics versus controls
Ten studies (N = 933) investigated the effect of probiotic
administration versus no probiotic (Control group)
[38,40,44-46,48,50-52,55].
Primary outcomes: growth parameters
(i) Weight gain
Four studies [24,44,50,55] reported weight gain
(g/day) for boys and girls separately. The results
from these four studies were pooled in meta-e 6 Probiotics versus controls, outcome: Weight gain (g/ day) for girls.analyses separately for boys and girls. Probiotics
failed to significantly increase weight gain
compared to the controls for boys (MD 1.64,
95% CI: -0.36 to 3.64 n = 158), no statistically
significant heterogeneity was detected between the
studies for boys (Chi2=3.43, df=3, p=0.33, I2=13%).
However, statistically significant heterogeneity was
observed for girls (Chi2=9.90, df=3, p=0.02,
I2=70%). An investigation of heterogeneity using
subgroup analysis with respect to the type of
formula (normal/ acidified/ reduced protein)
yielded the following results. Two studies [24,44]
showed that normal formula with probiotics failed
to significantly increase weight gain compared to
the controls for girls (MD 1.33, 95% CI: -0.76 to
3.41, n = 113) with no significant heterogeneity
between the two studies (Chi2=0.08, df=1, p=0.78,
I2=0%). Urban 2008 [50] showed that acidified
formula with probiotics significantly increased
weight gain in probiotic group compared to
controls for girls (MD 5.30, 95% CI: 0.46 to 10.14,
n = 28). Ziegler 2003 [55] showed that reduced
protein formula with probiotics significantly
reduced weight gain compared to controls for girls
(MD −4.80, 95% CI: -9.18 to −0.42, n = 29)
(Figure 6).(ii) Length gain
Four studies [24,44,50,55] reported length gain
for boys and girls separately. Two studies reported
in terms of mm/month and two studies reported
in terms of mm/day. The latter two studies
results were converted to mm/month by
multiplying both the mean and SD by 28, assuming
a 4 week/ 28-day month. Results from these four
Mugambi et al. Nutrition Journal 2012, 11:81 Page 17 of 32
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for boys and girls. Probiotics failed to significantly
increase length gain compared to the controls
for both boys (MD −0.37, 95% CI: -1.64 to 0.90,
n = 158) and girls (MD 0.32, 95% CI: -0.81 to 1.45,
n =165). No statistically significant heterogeneity
was detected between the studies for both boys
(Chi2=3.49, df=3, p=0.32, I2=14%) and girls
(Chi2=2.94, df=3, p=0.40, I2=0%).(iii) Head circumference gain
Three studies [24,44,50] reported length gain for
boys and girls separately. Two studies reported
in terms of mm/month and one study reported
in terms of mm/day. The latter study's results
were converted to mm/month by multiplying
both the mean and SD by 28 (assuming a 4 week/
28-day month). Probiotics failed to significantly
increase head circumference gain compared to
the controls for both boys (MD 0.76, 95% CI: -1.02
to 2.54, n = 125) and girls (MD 0.27, 95% CI: -0.70
to 1.23, n = 139). No statistically significant
heterogeneity was detected between the studies for
both boys (Chi2=3.87, df=2, p=0.14, I2=48%) and
girls (Chi2=1.12, df=2, p=0.57, I2=0%).Secondary outcomes
Tolerance to formula
(i) Stool frequency
Two studies [40,48] reported stool frequency
(evacuations per day) and meta-analysis of results from
these studies showed that probiotics failed to
significantly increase stool frequency compared to
controls (MD 0.01, 95% CI: -0.44 to 0.46, n = 120).
There was no significant heterogeneity between the
studies (Chi2=0.19, df=1, p=0.66, I2=0%). Since
Petschow 2005 [48] evaluated different probiotic
dosages, the highest dosage was chosen for the analysis.(ii) Stool consistency
One study [48] reported stool consistency score
(1–5: 1=hard, 2=formed, 3=soft, 4=loose,
5=watery). A calculated treatment effect showed
that there was no difference in consistency score
between the probiotic and control groups (MD
0.00, 95% CI: -0.33 to 0.33, n = 30).
Chouraqui 2008 [24] reported that liquid stools
occurred significantly more frequently in the
probiotic group compared to the control group (OR
2.79, 95% CI: 1.48 to 5.29, n = 64).
Ziegler 2003 [55] reported stool consistency in
terms of mean (SD) separately for hard, formed,
soft and liquid stools but no treatment effect was
calculated because the data was skewed (mean <
SD). Weizman 2006 [52] reported results for stoolconsistency score but again the data was skewed
(mean < SD).(iii)Episodes of diarrhoea
Ziegler 2003 and Weizman 2005 [52,55] reported
episodes of diarrhoea in terms of mean (SD) but no
meta-analysis was done because their results show
that the data was skewed (mean < SD).
Chouraqui 2004 and Chouraqui 2008 [24,40]
reported the frequency of diarrhoea but meta-
analysis of their results showed no benefit from
probiotic treatment compared to controls (RR 0.80,
95% CI: 0.46 to 1.38, n = 209). No statistically
significant heterogeneity was detected between the
studies (Chi2=0.61, df=1, p=0.44, I2=0%).(iv) Incidence of colic, spitting up / regurgitation,
vomiting, crying
Chouraqui 2004 [40] reported the number of
infants having spitting or regurgitation and there
was no difference observed between the probiotic
and control groups (RR 0.80, 95% CI: 0.26 to 2.42,
n = 90). Weizman 2006 [52] reported the daily
crying episodes and there were significantly less
crying episodes in favour of the control group
(MD 0.60, 95% CI: 0.20 to 1.00, n = 59). The results
from the two probiotic groups were combined
before meta-analysis. Gibson 2009 [44] reported
that stools, colic, spitting up, vomiting, restlessness
occurred at similar frequencies in the two groups
(data not shown in report). Ziegler 2003 [55]
reported that that there was no significant
formula effects on crying and colic (data not
shown in report).(v) Average formula intake
One study [38] reported the average formula intake
(ml/kg body-weight /day) and the calculated
treatment effect showed no differences between the
probiotic and control groups (MD 5.00, 95% CI:
-12.60 to 22.60, n = 58). Two studies [44,51]
reported the average formula intake (ml/day) and
meta-analysis showed that infants in the probiotic
group had a significantly higher formula intake
compared to the controls (MD 46.74, 95% CI:
23.93 to 69.54, n = 292). No statistically significant
heterogeneity was detected between the studies
(Chi2=0.45, df=1, p=0.50, I2=0%).Infections
(i) Infections
One study [44] reported the number of infants
having respiratory infections and the calculated
treatment effect showed no differences between the
probiotic and control groups (RR 0.93, 95% CI:
0.74 to 1.17, n = 142). One study [51] reported
Figu
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(95% CI). The mean (95% CI) were used in
calculating the SDs. However, no treatment effect
was calculated because the data was skewed (mean <
SD). One study [44] reported the number of infants
having gastrointestinal infections and the calculated
treatment effect showed no differences between the
probiotic and control groups (RR 0.70, 95% CI:
0.45 to 1.11, n = 142).(ii) Antibiotic intake
One study [51] reported prescription of antibiotics
in terms of mean (95% CI). The mean (95% CI)
were used in calculating the SDs. However, no
treatment effect was calculated because the data
was skewed (mean < SD).Hospitalization
Only one study [55] reported hospitalization but no
treatment effect was calculated because the data was
skewed (mean < SD)
Changes in gastrointestinal microflora
(i) Bifidobacteria
Two studies [38,46] reported results for bifidobacteria
measured as log10 (CFU) per gram stool. A meta-
analysis showed that the control group had
significantly increased counts of bifidobacteria
compared to probiotic group. (MD −1.27, 95% CI:
-2.03 to −0.51, n = 57). No statistically significant
heterogeneity was detected between the studies
(Chi2=0.71, df=1, p=0.40, I2=0%) [Figure 7].(ii) Lactobacillus
Only one study [38] reported results for
lactobacillus, measured as log10 (cfu) per gram
stool and the calculated treatment effect showed
that probiotics failed to increase the counts of
Lactobacillus compared to the controls (MD 0.22,
95% CI: -0.72 to 1.16, n = 41).Pathogens
(iii) EnterobacteriarTwo studies [38,46] reported results for
enterobacteria measured as log10 (cfu) per grame 7 Probiotics versus controls, outcome: Bifidobacteria -log10(CFU) perstool and meta-analysis showed that probiotics
significantly reduced counts of Enterobacteria
compared to the controls (MD −0.61, 95% CI:
-1.20 to −0.03, n = 51). No statistically significant
heterogeneity was detected between the studies
(Chi2=0.62, df=1, p=0.43, I2=0%).(iv) Bacteriodes
Two studies [38,46] reported results for bacteriodes
measured as log10 (cfu) per gram stool and meta-
analysis showed that probiotics failed to significantly
reduce counts of Bacteriodes compared to the
controls (MD −0.11, 95% CI: -1.01 to 0.78, n = 51).
No statistically significant heterogeneity was detected
between the studies (Chi2=0.95, df=1, p=0.33, I2=0%).Prebiotics versus controls
Twelve studies (N = 1563) investigated the effect of pre-
biotic administration versus placebo or no prebiotic in for-
mula (Control group) [32,35,37,39,41-43,47,49,53,54,56].
Primary outcomes: growth parameters
(i) Weight gain
Eight studies [32,35,41,42,47,49,54,56] reported
weight gain (g/day) and meta-analysis of their results
showed that prebiotics significantly increased weight
gain compared to the controls (MD 0.97, 95% CI:
0.24 to 1.70, n = 861). No statistically significant
heterogeneity was detected between the studies
(Chi2=4.67, df=7, p=0.70, I2=0%). Three studies
[35,42,56] evaluated different types of prebiotics
(acidic oligosaccharides with maltodextrin or neutral
GOS FOS, GOS FOS, GOS with polydextrose alone
or with lactulose). The results for the prebiotics
in each of these studies were combined before
meta-analysis using combined mean and pooled
standard deviation (Figure 8).(ii) Length gain
Seven studies [32,35,41,42,47,49,54] reported
length gain either as cm/week or in units that were
converted to cm/week. Meta-analysis of their
results showed that prebiotics failed to significantly
increase length gain compared to the controls (MD
0.01, 95% CI: -0.01 to 0.04, n = 697). No
statistically significant heterogeneity was detectedgram of stool.
Figure 8 Prebiotics versus controls, outcome: weight gain (g/day).
Table
Stool fr
Stool c
Stool c
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I2=0%). Two studies [35,42] each evaluated
different types of prebiotics (Acidic
oligosaccharides 0.2 g/dl with maltodextrin, acidic
oligosaccharides 0.2 g/dl with neutral GOS FOS
0.6 g/dl; GOS, FOS 0.4 g/dl and GOS FOS 0.8 g/
dl). The results for the prebiotics in each of these
studies were combined before meta-analysis using
combined mean and pooled standard deviation.(iii) Head circumference gain
Three studies [32,41,49] reported head
circumference gain either as cm/week or in units
that were converted to cm/week. Meta-analysis of
their results showed that prebiotics failed to
significantly increase head circumference gain
compared to the controls (MD −0.01, 95% CI:
-0.02 to 0.00, n = 438). No statistically significant
heterogeneity was detected between the studies
(Chi2=2.18, df=2, p=0.34, I2=8%).
Results from Ziegler 2007 [56] were not used
because they reported head circumference gain
only at 30 days and not at the end of treatment
period which was 120 days. (All other studies
reported results for end of treatment period).Secondary outcomes
Tolerance to formula
(i) Stool frequency
Four studies [32,35,43,56] reported stool frequency
(evacuations per day) and meta-analysis of their6 Stool characteristics
Costalos 200841: Median (range) st
Prebiotics (n=70)
equency 1.9 (1.2-2.1)
onsistency 3 (2–3.5)
Moro 200235: Median (IQR) Stool
Prebiotic1 (n=30)
onsistency score 3 (1.5)results showed that prebiotics significantly increased
stool frequency compared to the controls (MD 0.18,
95% CI: 0.06 to 0.30, n = 539). No statistically
significant heterogeneity was detected between the
studies (Chi2=2.97, df=3, p=0.40, I2=0%). Two
studies [35,56] each evaluated different types of
prebiotics (GOS FOS; GOS with polydextrose alone
or with lactulose). The results for the prebiotics
in each of these studies were combined before meta-
analysis using combined mean and pooled standard
deviation.
Costalos 2008 [41] reported the median (range) of
stool frequency (Table 6).(ii) Stool consistency
Results from the two studies [32,42] using a 5-point
scale (1=watery, 2=soft, 3=seedy, 4=formed, 5=hard)
were pooled in a meta-analysis but due to significant
heterogeneity detected between the two studies,
their results are reported separately. Stools from the
prebiotic group were significantly softer compared
to controls for both Fanaro 2005 [42] (MD −1.20,
95% CI: -1.61 to −0.79, n = 46) and Moro 2006 [32]
(MD −0.78, 95% CI: -1.00 to −0.56, n = 206). Fanaro
2005 [42] evaluated two types of prebiotics (acidic
oligosaccharides with maltodextrin or neutral GOS
FOS), the results for the prebiotics were combined
before meta-analysis using combined mean and
pooled standard deviation.
Fanaro 2008 [43] used an opposite 5 point scale
(1=hard, 2=formed, 3=seedy, 4=soft, 5=watery) and
reported the mean (SD) of area under the curve.ool characteristics
Controls (n=70)
1.6 (1.1-1.9)
3.1 (2.5-3.5)
consistency score
Prebiotic2 (n=27) Control (n=33)
2.5 (0.75) 4 (1.5)
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from the prebiotic group were significantly softer
compared to controls (MD 0.53, 95% CI: 0.31 to
0.75, n = 88).
Results from two studies [54,56] used a 4-point
scale (1=watery, 2=soft, 3=seedy, 4=formed) were
pooled in a meta-analysis but due to significant
heterogeneity detected between the two studies,
their results are reported separately. Stools from the
prebiotic group were significantly softer compared
to controls for both Xiao-Ming 2008 [54] (MD
−0.65, 95% CI: -0.87 to −0.43, n = 82) and Ziegler
2007 [56] (MD −0.25, 95% CI: -0.44 to −0.06,
n = 157). Ziegler 2007 [56] evaluated two types
of prebiotics (GOS with polydextrose alone or
with lactulose). The results for the prebiotics
were combined before meta-analysis using
combined mean and pooled standard deviation.
Costalos 2008 [41] reported the median (range)
of stool consistency score (Table 6).
Moro 2002 [35] reported the median (IQR) of
stool consistency score (Table 6).(iii)Diarrhoea
Two studies [39,56] reported the number of infants
having diarrhoea and a meta-analysis showed that
prebiotics failed to significantly decrease the
incidence of diarrhoea compared to the controls
(RR 0.62, 95% CI: 0.19 to 1.99, n = 237). No
statistically significant heterogeneity was detected
between the studies (Chi2=1.65, df=1, p=0.20,
I2=39%). Since Ziegler 2007 [56] evaluated two
types of prebiotics (GOS with polydextrose alone or
with lactulose), the number of events and totals for
the prebiotics were summed before meta-analysis.(iv) Incidence of colic, spitting up / regurgitation,
vomiting, crying
Moro 2006 [32] reported no vomiting and very
few infants crying but the number of infants
experiencing regurgitation were significantly reduced
in the prebiotic group compared to the control group
(RR 0.11, 95% CI: 0.02 to 0.49, n = 206).
According to Xiao-Ming 2008 [54], there was no
difference in crying score (MD 0.01, 95% CI: -0.00
to 0.02, n = 82), regurgitation score (MD −0.01, 95%
CI: -0.27 to 0.25, n = 82), and vomiting score (MD
−0.03, 95% CI: -0.21 to 0.15, n = 82) between the
prebiotic and control groups. All scores were 3
point scores. Crying score: 1= practically not crying,
2 = crying in connection to feeding, 3 = crying
independently from meals. Regurgitation score:
1 = no regurgitation, 2 = 1–2 regurgitations, 3 = > 2
regurgitations per day. Vomiting score: 1= no
vomiting, 2 = 1 episode of vomiting, 3 = >1 episode
of vomiting.Ziegler 2007 [56] reported that none of the infants
had colic; the numbers having excessive spitting
were too few; vomiting was similar between the
two groups (RR 1.12, 95% CI: 0.43 to 2.89, n = 32).
The prebiotic results were summed for the two
types before calculation of treatment effect.
Both Moro 2002 and Fanaro 2005 [35,42] reported
no difference in the incidence of crying,
regurgitation and vomiting episodes (data values
not shown in study reports).(v) Average formula intake
Five studies [35,38,47,49,54] reported formula
intake (ml/kg body-weight/ day) and meta-analysis
of their results showed statistically significant
heterogeneity between the studies (Chi2=10.80,
df=4, p=0.03, I2=63%,). Sensitivity analysis by
removing the one study [49] showing significantly
less formula intake for the prebiotics (MD −21.00,
95% CI: -31.86 to −10.14, n = 101) yielded no
significant heterogeneity between the four
remaining studies (Chi2=1.79, df=3, p=0.62, I2=0%)
but no significant difference between the two
groups (MD 0.31, 95% CI: -8.40 to 9.02, n = 269).
The prebiotic results for the two types of
prebiotics (GOS, FOS 0.4 g/dl, GOS FOS 0.8 g/dl)
in Moro 2002 [35] were combined before
meta-analysis using combined mean and pooled
standard deviation.Infections
(i) Infections
According to Moro 2006 [32], prebiotics
significantly reduced overall infections compared
to the controls (RR 0.45, 95% CI: 0.29 to 0.69,
n = 204). The number of infants having
gastrointestinal infections, urinary tract infections
(UTI) and otitis media were very few [32].
Two studies [32,39] reported the number of
infants with upper respiratory tract infections
(URTI) and their results were pooled in a
meta-analysis. However, due to significant
heterogeneity detected between the two studies
(Chi2=7.69, df=1, p=0.006, I2=87%), their results
are reported separately. Although Moro 2006 [32]
showed that the prebiotic group significantly
reduced the number of infants with URTI compared
to the controls (RR 0.48, 95% CI: 0.27 to 0.84,
n = 206), there was no difference between the two
groups according to Bruzzese 2009 [39] (RR 1.07,
95% CI: 0.86 to 1.33, n = 203).(ii) Antibiotic intake
According to Moro 2006 [32], prebiotics failed
to significantly reduce antibiotic intake compared
Figu
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n = 206).Changes in gastrointestinal microflora
(i) Bifidobacteria
Five studies [38,42,47,53,54] (n = 280) reported
Bifidobacteria (log10 CFU per gram stool) and their
results were pooled in a meta-analysis. However,
statistically significant heterogeneity was detected
between the studies (Chi2=60.23, df=4, p < 0.00001,
I2=93%). Heterogeneity persisted after conducting
subgroup analysis with respect to duration of
supplementation or dosage of treatment. The
results for each study are therefore reported
separately. Four studies showed that prebiotics
significantly increased bifidobacteria: Fanaro 2005
[42] (MD 0.30, 95% CI: 0.13 to 0.47, n = 46); Moro
2005 [47] (MD 2.70, 95% CI: 0.37 to 5.03, n = 32);
Xiao-Ming 2004 [53] (MD 1.90, 95% CI: 1.51 to
2.29, n = 121); Xiao-Ming 2008 [54] (MD 0.85, 95%
CI: 0.16 to 1.54, n = 38). The prebiotic results for
the two types of prebiotics (acidic oligosaccharides
with maltodextrin or neutral GOS FOS) in Fanaro
2005 [42] were combined before meta-analysis
using combined mean and pooled SD. However,
Brunser 2006 [38] showed no significant difference
in the number of bifidobacteria between the two
groups (MD −0.39, 95% CI: -1.49 to 0.71, n = 43)
[Figure 9].
Four studies reported their results in median;
therefore no conclusions could be made. Costalos
2008 [41] reported the median (range) of
Bifidobacteria (log10 CFU per gram stool) as a
percentage of total bacteria (Table 7). Three studies
[32,35,43] reported the median (IQR) of
Bifidobacteria (log10 CFU per gram stool) (Table 8).(ii) Lactobacillus
Three studies [38,53,54] reported Lactobacillus
(log10 CFU per gram stool) and meta-analysis
of their results showed statistically significant
heterogeneity between the studies (Chi2=26.44,
df=2, p < 0.00001, I2=92%). Sensitivity analysisre 9 Prebiotics versus controls, outcome: Bifidobacteria -log10(CFU) perwas done by removing the one study [38] that
showed no difference between the two groups
(MD −0.30, 95% CI: -1.08 to 0.48, n = 43). This
yielded no significant heterogeneity (Chi2=0.33,
df=1, p =0.57, I2=0%) between the remaining two
studies. Meta-analysis showed that prebiotics
significantly increased lactobacillus counts
compared to the controls (MD 1.96, 95% CI: 1.58
to 2.34, n = 159).
Three studies reported their results in median;
therefore no conclusions could be made. Fanaro
2008, Moro 2002 and Moro 2006 [32,35,43]
reported the median (IQR) of Lactobacillus (log10
CFU per gram stool) (Table 8).Pathogens
(iii)Enterobacteria
According to Brunser 2006 [38], there was no
difference in the number of Enterobacteria counts
between the prebiotic and control groups (MD
−0.48, 95% CI: -1.88 to 0.22, n = 43). Fanaro 2008
[43] reported the median (IQR) of Enterobacteria
(log10 CFU per gram stool) (Table 8).(iv) Bacteriodes
According to Brunser 2006 [38], there was no
difference in the number of Bacteriodes between the
prebiotic and control groups (MD −0.35, 95% CI:
-1.40 to 0.70, n = 43). Fanaro 2008 [43] reported the
median (IQR) of Bacteriodes (log10 CFU per gram
stool) (Table 8).(v) E. coli
Two studies [53,54] reported E. coli (log10 CFU per
gram stool) and their results were pooled in a meta-
analysis. However, statistically significant heterogeneity
was detected between the studies (Chi2=5.96, df=1,
p=0.01, I2=83%). The results are therefore reported
separately. Xiao-Ming 2004 [53] showed that
prebiotics significantly reduced E. coli counts
compared to the controls (MD −0.90, 95% CI: -1.29
to −0.51, n = 121) while Xiao-Ming 2008 [54] showed
no significant difference between the two groups
(MD 0.67, 95% CI: -0.53 to 1.87, n = 38).gram stool.
Table 7 Summary of findings table: Synbiotic studies
Effects of infant formula containing Synbiotics on clinical outcomes in full term infants
Patient or population: Full term infants, Settings: Multi-centre trials, Intervention: Infant formula with synbiotics, Comparison: Conventional infant formula
Outcomes Illustrative comparative risks* (95% CI) Measure of effect
(95% CI)
No of Participants
(studies)
Quality of the
evidence (GRADE)Assumed risk Corresponding risk
Conventional formula Infant formula with synbiotics
Weight gain (g/day) for boys The mean (SD) weight gain (g/day)
in control group was 30.9 (6.1)
Mean (SD) weight gain in synbiotic
group was 31.8 (5.9)
MD (95% CI):
0.90 (−1.95 to 3.75)
81 (1 study) ⊝⊝
low1,2Follow-up: mean 4 months
Weight gain (g/day) for girls The mean (SD) weight gain (g/day)
in control group was 26.9 (6)
Mean (SD) weight gain in synbiotic
group was 27.8 (6)
MD (95% CI):
0.90 (−1.81 to 3.61)
86 (1 study) ⊝⊝
low3,4Follow-up: mean 4 months
Length gain (mm/mo) for boys The mean (SD) length gain
(mm/month for boys in control group
ranged from 32.6 (3.6) to 35.1 (4.4)
The mean length gain (mm/mo) for
boys in the intervention groups was
0.75 higher (0.66 lower to 2.17 higher)
MD (95% CI):
0.75 (−0.66 to 2.17)
120 (2 studies) ⊝⊝
low5,6,7Follow-up: mean 4 months
Length gain (mm/mo) for girls The mean length gain (mm/month)
for girls in the control groups ranged
from 31.2 (3.7) to 32.2 (4.6)
The mean length gain (mm/mo) for
girls in the intervention groups was
0.75 higher (0.63 lower to 2.13 higher)
MD (95% CI):
0.75 (−0.63 to 2.13)
138 (2 studies) ⊝⊝
low8,9,10Follow-up: mean 4 months
Head circumference gain (mm/mo) for boys The mean head circumference gain
(mm/month) for boys in the control
groups ranged from 17.4 (2.9) to
18.4 (2.3)
The mean head circumference gain
(mm/mo) for boys in the intervention
groups was 0.06 lower (0.96 lower to
0.85 higher)
MD (95% CI):
-0.06 (−0.96 to −0.85)
126 (2 studies) ⊝⊝
Follow-up: 4 to 6 months
Head circumference gain (mm/mo) for girls The mean head circumference gain
(mm/month) for girls in the control
groups ranged from 15.5 (3) to
16.7 (2.4)
The mean head circumference gain
(mm/mo) for girls in the intervention
groups was 0.05 lower (0.94 lower to
0.85 higher)
MD (95% CI):
-0.05 (−0.94 to 0.85)
138 (2 studies) ⊝⊝
low13,14Follow-up: 4 to 6 months
Stool frequency (evacuations per day) The mean (SD) stool frequency
(evacuations per day) in the control
group ranged from 1.4 (0.49) to
1.8 (0.9)
The mean stool frequency (evacuations
per day) in the intervention groups was
0.28 higher (0.08 to 0.48 higher)
MD (95% CI):
0.28 (0.08 to 0.48)
176 (2 studies) ⊝⊝
low15,16Follow-up: 4 to 6 months
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison
group and the measure of effect of the intervention (and its 95% CI).CI: Confidence interval, MD: Mean Difference.
GRADE Working Group grades of evidence. High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact
on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change
the estimate. Very low quality: We are very uncertain about the estimate.
1 Small sample size n=81, 95% CI includes no effect.
2 Possible publication bias.
3 Small sample size n=86, 95% CI includes no effect.
4 Possible publication bias.
5 Allocation concealment not described in 2 studies.
6 Small sample size n=126.
7 Possible Publication bias.
8 Allocation concealment not described in 2 studies.
9 Small sample size n=138.
10 Possible Publication bias.
11 Small sample size n=126.
12 Possible publication bias.
13 Small sample size n=138.
14 Possible publication bias.
15 Small sample size n=176.
16 Possible publication bias.
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Table 8 Gastrointestinal microflora
Costalos 200841: Median (range) as % of total bacteria
Prebiotics (n=70) Controls (n=70)
% Bifidobacteria 39.69 (0–143.3) 14.87 (0–101)
% E.coli 1.95 (0–69.32) 4.06 (0–59.31)
Fanaro 200843: Median (IQR) microflora -log10(CFU) per gram stool
Prebiotics (n=56) Controls (n=59)
Bifidobacteria 9.86 (8.99-10.18) 9.38 (8.35-9.90)
Lactobacilli 4.62 (2–6.5) 4 (2–5.05)
Bacteriodes 7.95 (6.64-9.6) 8.16 (6.3-9.04)
Clostridia 4.3 (3–5.28) 4.29 (2.48-5.43)
Enterobacteria 8.65 (8.12-9.13) 8.53 (7.96-9.01)
E. coli 8.50 (7.9-8.99) 8.33 (7.59-8.83)
Moro 200235: Median (IQR)
Prebiotic1 (n=30) Prebiotic2 (n=27) Control (n=33)
Bifidobacteria 9.3 (1.6) 9.7 (0.8) 7.2 (4.9)
Lactobacilli 5.9 (1.5) 5.6 (2.1) 3.4 (1.8)
Moro 200632: Median (IQR) log10(CFU) per gram stool
Prebiotics (n=50) Controls (n=44)
Bifidobacteria 10.28 (0.7) 8.65 (1.2)
Lactobacilli 5.99 (3.6) 5.9 (2)
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therefore no conclusions could be made. Costalos
2008 [41] reported the median (range) of E. coli
(log10 CFU per gram stool) as a percentage of total
bacteria (Table 8). Fanaro 2008 [43] reported the
median (IQR) of E. coli and clostridia (log10 CFU
per gram stool) (Table 8).Discussion
The objectives of this systematic review were to deter-
mine the effects of infant formula containing probiotics,
prebiotics or both (synbiotics) on clinical outcomes in
full term infants and to explore if synbiotics are superior
over probiotics or prebiotics. Studies that used breast
milk or mixed feeds (breast and infant formula or other
types of milk) were excluded. All included RCTs evalu-
ated either synbiotics, probiotics or prebiotics use in full
term infants. The studies varied in enrolment criteria,
sample size, intervention and treatment duration.
Summary of main findings
Synbiotics
Addition of synbiotics to infant formula did not have
any significant effect on growth (weight gain, length
and head circumference). Synbiotics significantly
increased stool frequency. However, two studies
[21,25] reported no differences in stool consistency,
while one study [24] reported an increase in liquid
stools in synbiotic group. There were no significantdifferences between study groups on the incidence and
frequency of colic, spitting up / regurgitation, crying,
restlessness or vomiting. The effect of synbiotics on
the volume of formula tolerated was not reported. Ef-
fect of synbiotics on frequency of infections was under
reported. In one study [25], there were no differences
in the frequency of infections between study groups,
while in another study [21], the treatment effect could
not be calculated or any conclusions made on the fre-
quency of infections or antibiotic intake. Effects of
synbiotics on hospitalization, GI microflora and im-
mune response were not reported in any study there-
fore these parameters could not be evaluated.
Interpreting the effects of synbiotic supplementation
of infant formula on clinical outcomes was difficult due
to the limited number of studies. The synbiotic studies
had short treatment duration (4 to 6 months) and treat-
ment varied in all 3 studies. There was not enough
evidence to state that synbiotics in infant formula have a
significant effect on growth or lower the incidence of
colic, spitting up / regurgitation, crying, restlessness.
There is limited evidence that synbiotics do increase
stool frequency and effects on stool consistency were in-
conclusive. There is not enough evidence to state that
synbiotics reduce the risk of infections or decrease use
of antibiotics. There is no data on the effects of synbio-
tics on GI microflora. The available data is very limited
to draw reliable conclusions on the effects of synbiotics
on clinical outcomes in formula fed infants.
Table 9 Summary of findings table: probiotic studies
Effects of infant formula containing Probiotics on clinical outcomes in full term infants
Patient or population: Full term infants, Settings: Multi-centre trials (hospitals), Intervention: Infant formula with probiotics, Comparison: Conventional infant formula
Outcomes Illustrative comparative risks* (95% CI) Measure of
effect (95% CI)
No of Participants
(studies)
Quality of the
evidence (GRADE)Assumed risk Corresponding risk
Conventional formula Infant formula with probiotics
Weight gain (g/day) for boys The mean (SD) weight gain
(g/day) for boys in the control
group ranged from 30.9 (6.1)
to 32.8 (4.1)
The mean weight gain (g/day) for
boys in the intervention groups was
1.64 higher (0.36 lower to 3.64 higher)
MD (95% CI):
1.64 (−0.36 to 3.64)
158 (4 studies) ⊝⊝
low1,2Follow-up: 4 to 7 months
Weight gain (g/day) for girls The mean (SD) weight gain
(g/day) for girls in the control
group ranged from 26.5 (4.9)
to 29 (6.3)
The mean weight gain (g/day) for girls
in the intervention groups was
0.76 higher (2.57 lower to 4.09 higher)
MD (95% CI):
0.76 (−2.57 to 4.09)
170 (4 studies) ⊝⊝
low3,4,5Follow-up: 4 to 7 months
Length gain (mm/month) for boys The mean (SD) length gain
(mm/month) for boys in the
control group ranged from
31.36 (4.48) to 37.3 (4.9)
The mean length gain (mm/month)
for boys in the intervention groups
was 0.37 lower (1.64 lower to 0.9 higher)
MD (95% CI):
-0.37 (−1.64 to 0.90)
158 (4 studies) ⊝⊝
low6,7Follow-up: 4 to 7 months
Length gain (mm/month) for girls The mean (SD) length gain
(mm/month) for girls in the
control group ranged from
28 (3.64) to 32 (4.6)
The mean length gain (mm/month)
for girls in the intervention groups was
0.32 higher (0.81 lower to 1.45 higher)
MD (95% CI):
0.32 (−0.81 to 1.45)
165 (4 studies) ⊝⊝
low8,9Follow-up: 4 to 7 months
Head circumference gain (mm/month) for boys The mean (SD) head
circumference gain (mm/month)
for boys in the control group
ranged from 17.5 (3.4) to 35.28 (7)
The mean head circumference gain
(mm/month) for boys in the intervention
groups was 0.76 higher (1.02 lower to
2.54 higher)
MD (95% CI):
0.76 (−1.02 to 2.54)
125 (3 studies) ⊝⊝
low10,11Follow-up: 4 to 7 months
Head circumference gain (mm/month) for girls The mean (SD) head
circumference gain (mm/month)
for girls in the control group
ranged from16 (3) to 36.68 (15.4)
The mean head circumference gain
(mm/month) for girls in the intervention
groups was 0.27 higher (0.7 lower to
1.23 higher)
MD (95% CI):
0.27 (−0.70 to 1.23)
139 (3 studies) ⊝⊝
low12,13Follow-up: 4 to 7 months
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Table 9 Summary of findings table: probiotic studies (Continued)
Bifidobacteria -log10(CFU) per gram of stool The mean (SD) bifidobacteria
-log10(cfu) per gram of stool in
the control group ranged 9.75 (0.5)
to 10.11 (1.67)
The mean bifidobacteria -log10(cfu) per
gram of stool in the intervention groups
was 1.27 lower (2.03 to 0.51 lower)
MD (95% CI):
-1.27 (−2.03 to −0.51)
57 (2 studies) ⊝⊝
low14, 15
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison
group and the measure of effect of the intervention (and its 95% CI). CI: Confidence interval, CFU: colony forming units, MD: Mean Difference, RR: Risk ratio.
GRADE Working Group grades of evidence. High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact
on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change
the estimate. Very low quality: We are very uncertain about the estimate.
1 Small sample size n=158, 95% CI includes no effect.
2 Possible publication bias.
3 Unexplained heterogeneity).
4 Small sample size n=170.
5 Possible publication bias.
6 Small sample size n=158, 95% CI includes no effect.
7 Possible publication bias.
8 Small sample size n=165, 95% CI includes no effect.
9 Possible publication bias.
10 Small sample size n=125, 95% CI includes no effect.
11 Possible publication bias.
12 Small sample size n=139.
13 Possible publication bias.
14 Small sample size n=57.
15 Possible publication bias.
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Table 10 Summary of findings table: prebiotic studies
Effects of infant formula containing Prebiotics on clinical outcomes in full term infants
Patient or population: Full term infants, Settings: Multi-centre trials, Intervention: Infant formula with prebiotics, Comparison: Conventional formula
Outcomes Illustrative comparative risks* (95% CI) Measure of
effect (95% CI)
No of Participants
(studies)
Quality of the
evidence (GRADE)Assumed risk Corresponding risk
Conventional formula Infant formula with prebiotics
Weight gain (g/day) The mean (SD) weight gain (g/day)
in the control group ranged from
26.4 (3.7) to 40.59 (3.95)
The mean weight gain (g/day) in the
intervention groups was 0.97 higher
(0.24 to 1.7 higher)
MD (95% CI):
0.97 (0.24 to 1.70)
861 (8 studies) ⊝⊝
low1,2,3Follow-up: 1 to 6 months
Length gain (cm/week) The mean (SD) length gain
(cm/week) in the control group
ranged from 0.74 (0.1) to 0.96 (0.11)
The mean length gain (cm/week) in
the intervention groups was
0.01 higher (0.01 lower to 0.04 higher)
MD (95% CI):
0.01(−0.01 to 0.04)
697 (7 studies) ⊝⊝
low4,5,6Follow-up: 1 to 6 months
Head circumference gain (cm/ week) The mean (SD) head circumference
gain (cm/ week) in the control
group ranged from 0.34 (0.05) to
0.63 (0.1)
The mean head circumference gain
(cm/ week) in the intervention groups
was 0.01 lower (0.02 lower to 0 higher)
MD (95% CI):
-0.01 (−0.02 to 0.00)
438 (3 studies) ⊝⊝
low7,8Follow-up: 1.5 to 6 months
Stool frequency (evacuations per day) The mean (SD) stool frequency
(evacuations per day) in the control
group ranged from1.5 (0.6) to 2.4 (1.64)
The mean stool frequency (evacuations
per day) in the intervention groups was
0.18 higher (0.06 to 0.3 higher)
MD (95% CI):
0.18 (0.06 to 0.30)
579 (4 studies) ⊝⊝
low9,10Follow-up: 1 to 6 months
Diarrhea Study population RR 0.62 (0.19 to 1.99) 237 (2 studies) ⊝⊝
low11,12Follow-up: 4 to 12 months 23 per 100 14 per 100 (4 to 46)
Moderate
19 per 100 12 per 100 (4 to 38)
URTI Study population RR 0.74 (0.32 to 1.73) 409 (2 studies) ⊝⊝
Follow-up: 6 to 12 months low13, 14, 1545 per 100 33 per 100 (14 to 77)
Moderate
44 per 100 33 per 100 (14 to 76)
Bifidobacteria -log10(CFU) per gram stool The mean(SD) bifidobacteria -log10(cfu)
per gram stool in the control group
ranged from 6(0.9) to 10.11 (1.67)
The mean bifidobacteria -log10(cfu)
per gram stool in the intervention groups
was 0.92 higher (0.02 lower to 1.86 higher)
MD (95% CI):
0.92 (−0.03 to 1.86)
280 (5 studies) ⊝⊝
low16, 17, 18Follow-up: 1 to 6 months
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Table 10 Summary of findings table: prebiotic studies (Continued)
Lactobacilli -log10(CFU) per gram stool The mean (SD) lactobacilli -log10 (cfu)
per gram stool in the control group
ranged from 3.95 (1.57) to 4.27 (2.02)
The mean lactobacilli -log10(cfu) per gram
stool in the intervention groups was
1.12 higher (0.44 lower to 2.67 higher)
MD (95% CI):
1.12 (−0.44 to 2.67)
202 (3 studies) ⊝⊝
low19,20,21Follow-up: 3 to 6 months
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison
group and the measure of effect of the intervention (and its 95% CI). CI: Confidence interval, CFU: Colony Forming Units, MD: Mean Difference, RR: Risk ratio.
GRADE Working Group grades of evidence: High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact
on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change
the estimate. Very low quality: We are very uncertain about the estimate.
1 Allocation concealment not clearly described in 6 studies.
2 Blinding not clearly demonstrated or described in 7 studies.
3 Possible publication bias.
4 Allocation concealment not clearly demonstrated in 5 studies.
5 Blinding not clearly demonstrated in 6 studies.
6 Possible publication bias.
7 Blinding not clearly described in 2 studies.
8 Possible publication bias.
9 Incomplete outcome data (with no reasons given for missing data) was present in 1 study.
10 Possible publication bias.
11 Small sample size n=237, 95% CI includes no effect.
12 Possible publication bias.
13 Unexplained heterogeneity.
14 95% CI includes no effect.
15 Possible publication bias.
16 Unexplained heterogeneity.
17 Small sample size n=280.
18 Possible publication bias.
19 Unexplained heterogeneity.
20 Small sample size n=202.
21 Possible publication bias.
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A limited number of studies analyzed the effects of pro-
biotic supplementation on growth by gender. These
studies had small sample sizes and the follow-up periods
were short. Addition of probiotics to infant formula did
not have any significant effect on growth (weight gain,
length gain or head circumference) in boys or girls. No
study reported any weight loss. Probiotic infant formula
was well tolerated. The limited available data shows that
probiotics did not have any significant effect on stool
frequency or consistency. Probiotic supplementation was
not associated with fewer episodes of diarrhoea, a lower
incidence of colic, spitting up / regurgitation, restless-
ness, vomiting. In one study [52] there were fewer crying
episodes in the control group than probiotic group. Pro-
biotic effects on infections, antibiotic use and length of
hospitalization were inconclusive. Probiotic supplemen-
tation did result in a significantly higher formula intake
compared to controls.
Effects of probiotic supplementation on intestinal
microflora were conflicting. Probiotics failed to increase
counts of bifidobacteria and lactobacillus. Probiotics sig-
nificantly reduced counts of enterobacteria but failed to
reduce counts of bacteriodes. None of the studies
reported on immune response (CRP, IL-6), therefore the
impact of probiotics on these parameters could not
be evaluated. All 10 probiotic studies used various
strains of bifidobacteria and lactobacillus with different
doses. Treatment duration also varied from 14 days to
7 months. This confirms the ESPGHAN Committee on
nutrition statement that there is a lack of published evi-
dence on clinical benefits from long term use of pro-
biotic containing infant formula [95]. Well designed long
term follow – up RCTs using similar treatment regimens
(same probiotics strains, dose and treatment duration)
are needed to establish the effects of probiotics on
healthy formula fed infants.
Prebiotics
Prebiotic addition to infant formula did have a signifi-
cant effect on weight gain but had no significant effect
on length and head circumference. None of the studies
reported any weight loss. Prebiotic supplementation
increased stool frequency but failed to improve stool
consistency or decrease incidence of diarrhoea. Prebiotic
supplementation did not reduce the incidence of spitting
up / regurgitation, vomiting or crying (no study reported
colic) or increased volume of formula tolerated. Pre-
biotic supplementation failed to significantly reduce
upper respiratory infections. However, one study [32]
did report a significant reduction in overall infections
and antibiotic intake. Prebiotics supplementation failed
to increase counts of bifidobacteria, lactobacillus or de-
crease the levels of pathogens (enterobacteria, bacteriodes,E – coli). None of the studies reported on hospitalization
(days in hospital) and immune response (CRP, IL-6), there-
fore the impact of prebiotics on these parameters could
not be evaluated.
Majority of the studies had a short treatment duration
ranging from 28 days to 12 months. The prebiotic doses
ranged from 0.15 g to 0.8 g/100 ml which did not exceed
the level recommended by the European Committee on
food in order to minimize intolerance and maximize the
bifidogenic effect of the prebiotic.
Quality of the evidence and potential biases in the review
process
We used guidelines from GRADE working group and
GRADEpro 3.6 software to assess the quality of evidence
in this review (Table 7, 9, 10). Overall the quality of evi-
dence for primary outcomes is low, meaning that further
research is very likely to have an important impact on
our confidence in the estimate of effect and is likely to
change the estimate. The quality of the evidence was
compromised by: Imprecision (majority of studies had a
small sample size ranging from 97 to 227 in the synbio-
tic studies, 54 to 201 in probiotic studies, 32 to 271 in
the prebiotic studies); limitations in study design and
execution (inadequate information was published to as-
sess methodological quality of the study. Information
was missing on sequence generation, allocation conceal-
ment, blinding, incomplete outcome data, selective
reporting, free of other bias domains; Inconsistency of
results); unexplained heterogeneity; use of different
study preparations (types of synbiotic, probiotic, prebio-
tics) and different doses regimens were used and publi-
cation bias.
At the conclusion of the review process and prepar-
ation of the manuscript (for this review), one on-going
study [96] was recruiting, one study [97] was not yet
recruiting, one study [98] was still on-going, no longer
recruiting. Therefore data from these studies could not
be included in this review. The reviewers used thorough
comprehensive search strategies adopted for the avail-
able databases. All attempts were made to minimize
publication bias. All steps of this review were conducted
independently by the reviewers. Only randomised con-
trolled studies were included in this review.
Breast feeding statement
By conducting this review on exclusively formula fed
infants, the authors do not seek to diminish the import-
ance of breastfeeding and promote formula feeding. The
reviewers acknowledge the importance of breastfeeding
for infants. They support exclusive breastfeeding for 6
months, thereafter safe complementary feeding from 6
months of age with continued breastfeeding up to 2
years and beyond as per the global recommendations for
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Children's Fund (UNICEF). This is because breastfeeding
is the ideal feeding method for infants [99].
Conclusion
There is not enough evidence to state that supplementa-
tion of term infant formula with synbiotics, probiotics or
prebiotics does result in improved growth and clinical
outcomes in full term infants. There is no data available
to establish if synbiotics are superior to probiotics or
prebiotics. Therefore this review does not support the
routine supplementation of term infant formula with
synbiotics, probiotics or prebiotics.
Implications for practice
Probiotics: The limited evidence shows synbiotic or pro-
biotic supplementation of infant formula did not have
any adverse effects, significant impact on growth or clin-
ical outcomes. All studies used different probiotic
strains, the effects of one type of probiotic cannot be
extrapolated to other types of probiotic bacteria. Pre-
biotic supplementation of infant formula also did not
result in any adverse effects on infants. There are
some clinical benefits such as improved weight gain and
stool frequency.
Implications for research
For clear recommendations to be made, well designed
large RCTs with long term follow - up are required on
exclusively formula fed term infants to investigate the ef-
fect of the same synbiotic combinations on clinical out-
comes; the effect of the same probiotics (with similar
doses and treatment duration) on clinical outcomes
because available studies used different probiotic doses
and treatment durations; the effect of the same prebio-
tics (with similar doses and treatment duration) on clin-
ical outcomes because available studies used similar
prebiotics with different doses and treatment duration;
the effects of synbiotics, probiotics or prebiotics on clin-
ical outcomes that have not been adequately addressed in
previous studies; if synbiotics are superior to probiotics or
prebiotics. Future RCTs should have treatment arms that
include both synbiotics, probiotic and prebiotics.
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